The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 December;65(4):402-9

DOI: 10.23736/S1824-4785.16.02894-6

language: English

Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria

Naelle LOMBION ¹, Philippe ROBIN ², Adrian TEMPESCUL ¹, Pierre-Yves LE ROUX ², Ulrike SCHICK ³, Gaëlle GUILLERM ¹, Jean-Christophe IANOTTO ¹, Christian BERTHOU ¹, Pierre-Yves SALAÜN ², Ronan ABGRAL ² ✉

ACCESS OPTIONS

Purchase access

You can access the full text of this article (PDF and HTML if available) for 48 hours at a price of € 45,00.

Downloading and printing for personal use allowed.

Regain access

Personal subscriptions

Access as an individual subscriber

Institutional access

Access through your institution

Subscribe to this journal

Subscribe to The Quarterly Journal of Nuclear Medicine and Molecular Imaging

Recommend to your librarian

top of page

YOUR ACCOUNT

YOUR ORDERS

SHOPPING BASKET

HOW TO ORDER

YOUR SUBSCRIPTIONS

YOUR ARTICLES

YOUR EBOOKS

COUPON

ACCESSIBILITY

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 December;65(4):402-9

Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria

Publication History

Cite this article as

Corresponding author e-mail

Share